Promotor methylation status of MAPK4 is a novel epigenetic biomarker for prognosis of recurrence in patients with thymic epithelial tumors

BACKGROUND: The prognosis of thymic epithelial tumors (TETs) currently relies on the commonly adopted WHO classification and Masaoka staging system, which cannot reflect the undefined biological behaviors limiting them as prognostic factors. METHODS: In this study, we first identified 40 genes and 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Guan, Wei, Li, Songlin, Zhang, Zhimin, Xiao, He, He, Juan, Li, Jian, He, Xuan, Luo, Jia, Liu, Yun, Lei, Lin, Ma, Jungang, Chen, Lizhao, Chen, Chuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575130/
https://www.ncbi.nlm.nih.gov/pubmed/36073321
http://dx.doi.org/10.1111/1759-7714.14628

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575130/
https://www.ncbi.nlm.nih.gov/pubmed/36073321
http://dx.doi.org/10.1111/1759-7714.14628

Ejemplares similares